# A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.

> **NCT03794440** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 595 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** IBI305
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT03794440
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-02-11
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 595 (ACTUAL)
- **Last updated:** 2021-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03794440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03794440, "A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03794440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*